Ray Dalio Royalty Pharma PLC Transaction History

Bridgewater Associates, LP

$17.3 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$26.26 - $29.9 $3.48 Million - $3.96 Million	-132,471 Reduced 35.66%	238,991 $6.3 Million
Q1 2024 May 14, 2024	BUY	$27.46 - $31.33 $9.62 Million - $11 Million	350,314 Added 1656.49%	371,462 $11.3 Million
Q4 2023 Feb 14, 2024	SELL	$26.21 - $29.22 $4.51 Million - $5.03 Million	-172,028 Reduced 89.05%	21,148 $594,000
Q3 2023 Nov 13, 2023	BUY	$26.26 - $31.38 $2.11 Million - $2.53 Million	80,538 Added 71.5%	193,176 $5.24 Million
Q2 2023 Aug 11, 2023	BUY	$29.6 - $36.56 $2.34 Million - $2.9 Million	79,201 Added 236.87%	112,638 $3.46 Million
Q1 2023 May 12, 2023	SELL	$32.77 - $39.4 $185,347 - $222,846	-5,656 Reduced 14.47%	33,437 $1.2 Million
Q4 2022 Feb 13, 2023	SELL	$39.17 - $44.04 $891,470 - $1 Million	-22,759 Reduced 36.8%	39,093 $1.54 Million
Q3 2022 Nov 10, 2022	BUY	$39.88 - $44.65 $2.25 Million - $2.52 Million	56,543 Added 1065.04%	61,852 $2.49 Million
Q2 2022 Aug 11, 2022	SELL	$37.53 - $44.22 $1.32 Million - $1.56 Million	-35,178 Reduced 86.89%	5,309 $223,000
Q1 2022 May 13, 2022	BUY	$37.46 - $42.44 $1.3 Million - $1.47 Million	34,739 Added 604.37%	40,487 $1.58 Million
Q4 2021 Feb 14, 2022	BUY	$35.17 - $42.48 $202,157 - $244,175	5,748 New	5,748 $229,000
Q3 2021 Nov 12, 2021	SELL	$36.14 - $42.24 $663,060 - $774,977	-18,347 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$39.85 - $46.63 $731,127 - $855,520	18,347 New	18,347 $752,000
Q1 2021 May 14, 2021	SELL	$42.34 - $52.82 $573,071 - $714,918	-13,535 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$36.12 - $50.05 $488,884 - $677,426	13,535 New	13,535 $677,000

Others Institutions Holding RPRX

# of Institutions

413

Shares Held

283M

Call Options Held

578K

Put Options Held

47.5K

View Full List

About Royalty Pharma plc

Ticker RPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 437,139,008
Market Cap $10.6B
Description
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...

More about RPRX

Track Ray Dalio's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.

Account